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Abstract
Background Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppu-
rating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar
presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and
delayed therapy.
Objectives Improved communication around the disease could facilitate self-diagnosis and a quicker response from
healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease.
Methods A HS awareness campaign was conducted for 2 years with the help of a media agency and a patients’
association.
Results Results confirm that a better communication has a strong impact on the disease awareness.
Conclusions This paper demonstrates that the more this disease awareness is carried on, the more quick, effective
and efficient the patient’s management could be.
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Introduction
Hidradenitis suppurativa (HS) is an inflammatory skin disease
with a characteristic clinical presentation of recurrent or chronic
painful or suppurating lesions in the apocrine gland-bearing
regions.1 The prevalence of HS is unknown and varies from
0.03% to 4%.2
Because of sparse epidemiologic data, disease burden of HS
has not yet been established, and its actual prevalence worldwide
is probably underestimated.
Surveys show that the mean delay in establishing a diagnosis
of HS from the time of its initial presentation is 7.2 years.3 This
may be due to insufficient awareness of HS and lower knowledge
throughout the general population about this disease or to the
fact that patients may accept recurrent symptoms that follow
standard treatments and not seek further care.
The importance of effective communication has already been
recognized by the medical literature during the last decades4–7;
the high value of the communication between the healthcare
practitioner and the patient has been highlighted,8 together with
the effectiveness of specific training courses to enhance health-
care practitioners’ communication skills. Besides, a new value
has been given to the so-called disease awareness,6–9 since the
increase of screenings is of course fundamental, but it is also
important to handle a communication which can lead to new
diagnosis.6–8 This takes us to the aim of the present paper, which
presents a new way to communicate with people through a com-
prehensive and integrated communication7–10 which takes
advantage from the use of a more ‘democratic’ word, like ‘cyst’,
also affecting the genital area, spread through social and mass
media.10 This impacts on the HS awareness, which positively
levers both on diagnosis skills and a more effective and efficient
patient’s management.
Methods/the Italian HS awareness campaign
The HS awareness campaign was conducted during a period of 2
years (2017 and 2018) by a media agency (Personal Media) with†HS Awareness Working Group members are listed in Appendix.
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the patronage of the patients’ association Inversa Onlus. This
campaign was intended to give the chance to exploit a free der-
matologic screening reserved for people suffering from HS – or
who think they may be suffering from this disease – and it took
place on the whole Italian territory in hospitals and medical cen-
tres which joined this initiative. The communication around it
was carried by using the more understandable term ‘cyst’,
instead of the HS one (Fig. 1), and it was developed by integrat-
ing mass media (television, radio and local newspapers), social
media (Facebook) and by continuously carrying out digital PR
and institutional relations (with hospitals and medical diagnos-
tic centres), whilst people could book, via telephone, a free
screening during special and dedicated open days (34 in 2017
and 31 in 2018).
Results and discussion
As shown in Table 1, the target of the campaign was heterogenous,
since during the open days the youngest person checked was
10 years old and the oldest was 78, and the M:F ratio was 38 : 62,
confirming the existing literature.11 Regarding communication
effectiveness, the 936 communication actions (546 in 2017 and 390
in 2018) were able to identify 555 new cases of HS (out of a poten-
tial 60 000 derived from the 20 million Facebook users, consider-
ing a minimal prevalence of 0.03%). Furthermore, the campaign
was also useful to spread knowledge about HS: through the dedi-
cated Facebook page and the information material (both printed
and web-based) in which HS was described and explained, the
selected users were able to consider whether they could be affected
by HS. This approach resulted in a strong impact on visit requests
by patients potentially suffering from HS and this is demonstrated
by the 2017 and 2018 results: the first year 688 screening reserva-
tions led to 299 (43.45% of the requests) new HS diagnoses, whilst
the 463 screening reservations during the second year led to 256
(55.3% of the requests) new diagnoses.
Conclusion
Results definitively confirm the literature6–9 and give an answer
to the demand coming from previous studies8: a better managed
communication has a strong impact on disease awareness and
improved disease awareness allows the healthcare structures to
better manage patients, with, for instance, the presence of spe-
cialized nurses and dedicated management teams.8 Furthermore,
the integrated communication campaign, developed by using
more understandable terminology, has improved the general
awareness around HS, which is often misdiagnosed, and its daily
care practices. As a result, the number of patients who take
action could potentially increase substantially. One factor in
whether or not patients seek help is the shame of the condition
during intimacy. Privacy issues should be taken in account, as
privacy policies on social media such as Facebook are very strict,
and could potentially impact campaigns.
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Number Communication
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Appendix
HS Awareness Working Group: Mauro Alaibac (Dermatology
Unit, University of Padova, Italy); Giuseppe Argenziano (Der-
matology Unit, University of Campania, Naples, Italy); Nicola
Giovanni Arpaia (Section of Dermatology, Miulli Regional
Hospital, Bari, Italy); Giovanni Bagnoni (Dermatology Unit,
Livorno Hospital, Livorno, Italy); Emilio Berti (Dermatologiy
Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Poli-
clinico, Milan, Italy); Luca Bianchi (Department of Dermatol-
ogy, University of Rome Tor Vergata, Rome, Italy); Daniela
Bianchini (Department of Dermatology and Venereology, La
Sapienza University of Rome, Rome, Italy); Piergiacomo Calza-
vara Pinton (Department of Dermatology, University of Brescia,
Italy); Serafinella Patrizia Cannavo (Section of Dermatology,
University of Messina, Italy); Maurizio Congedo (Section of
Dermatology, Vito Fazzi Hospital, Lecce, Italy); Salvatore Corrao
(Hospital Trust ARNAS Civico, Di Cristina, Benfratelli,
Palermo); Antonio Costanzo (Dermatology Unit, Humanitas
University and Humanitas Clinical and Research Center, Roz-
zano, Italy); Francesco Cusano (Department of Dermatology, G.
Rummo Hospital, Benevento, Italy); Salvo Dattola (Tiberio Evoli
Hospital, M. P. Salvo, Italy); Stefano Dattoli (Mater Domini
Hospital, Catanzaro, Italy); Salvatore Deledda (Dermatology
Clinic San Francesco Hospital ASL 3, Nuoro, Italy); Massimo
Donini (Department of Dermatology, SS Giovanni e Paolo Civil
Hospital, Venice, Italy); Gabriella Fabbrocini (Section of
Dermatology, Department of Clinical Medicine and Surgery,
University of Naples Federico II, Naples, Italy); Maria Teresa
Fierro (Dermatology Clinic, University of Turin, Italy); Caterina
Foti (Dermatology Clinic, University of Bari, Italy); Antonia
Gerarda Galluccio (Sacro Cuore Di Gesu Fbf Hospital, Bene-
vento, Italy); Alessandro Gatti (Department of Dermatology,
Hospital Ca’ Foncello, Treviso, Italy); Carlo Rene Girardelli
(Division of Dermatology, S. Chiara Hospital, Trento, Italy);
Giampiero Girolomoni (Section of Dermatology and Venereol-
ogy, University of Verona, Italy); Giuseppe Lemme (Carlo
Urbani Hospital, Jesi, Italy); Piergiorgio Malagoli (Dermatology
Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy);
Giovanna Malara (Department of Dermatology, Grande Ospe-
dale M. Morelli, Reggio Calabria, Italy); Santo Raffaele Mercuri
(Dermatology Unit, IRCCS San Raffaele, Milan, Italy); Giuseppe
Micali (Dermatology Clinic, University of Catania, Italy); Maria
Antonia Montesu (Dermatology Unit, University of Sassari,
Italy); Annamaria Offidani (Dermatology Unit, Polytechnic
Marche University, Ancona, Italy); Manuela Papini (Dermatol-
ogy Section, University of Perugia, Italy); Aurora Parodi
(Di.S.Sal. Section of Dermatology, University of Genoa, San
Martino Polyclinic Hospital, Genoa, Italy); Annalisa Patrizi
(Division of Dermatology, University of Bologna, Italy);
Giovanni Pellacani (Dermatology Unit, University of Modena
and Reggio Emilia, Modena, Italy); Ketty Peris (Institute of
Dermatology, Catholic University - Fondazione Policlinico
Universitario A. Gemelli IRCCS, Rome, Italy); Angelo Piccirillo
(San Carlo Hospital, Potenza, Italy); Paolo Pigatto (Dermatology
Unit, IRCCS Istituto Ortopedico Galeazzi, University of Milan,
Italy); Nicola Pimpinelli (Division of Dermatology, University of
Florence, Italy); Concetta Potenza (Dermatology Unit ‘Daniele
Innocenzi’, Sapienza University of Rome, Polo Pontino,
Terracina, Italy); Eugenio Provenzano (Dermatology Unit, A.O.
Cosenza, Italy); Marco Romanelli (Department of Dermatology,
University of Pisa, Italy); Franco Rongioletti (Dermatology
Clinic, University of Cagliari, Italy); Paola Savoia (Division of
Dermatology, University of Eastern Piedmont, Novara, Italy);
Marco Simonacci (Department of Dermatology, Macerata
Hospital, Macerata, Italy); Riccardo Sirna (Dermatology Section,
Misericordia Hospital, Grosseto, Italy); Giuseppe Stinco (Insti-
tute of Dermatology, ‘Santa Maria della Misericordia’ University
Hospital, Udine, Italy); Giancarlo Valenti (Dermatology Unit,
Pugliese Hospital, Catanzaro, Italy); Iris Zalaudek (Department
of Dermatology, University of Trieste, Italy).
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